1. Academic Validation
  2. An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia

An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia

  • Cancers (Basel). 2022 Feb 22;14(5):1113. doi: 10.3390/cancers14051113.
Abel Tesfaye Anshabo 1 Laychiluh Bantie 1 Sarah Diab 1 Jimma Lenjisa 1 Alemwork Kebede 1 Yi Long 1 Gary Heinemann 1 Jasmine Karanjia 1 Benjamin Noll 1 Sunita K C Basnet 1 Manjun Li 1 Robert Milne 1 Hugo Albrecht 1 Shudong Wang 1
Affiliations

Affiliation

  • 1 Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.
Abstract

Mutations in FMS-like tyrosine kinase 3 (FLT3) occur in approximately one-third of AML patients and are associated with a particularly poor prognosis. The most common mutation, FLT3-ITD, is a self-activating internal tandem duplication (ITD) in the FLT3 juxtamembrane domain. Many FLT3 inhibitors have shown encouraging results in clinical trials, but the rapid emergence of resistance has severely limited sustainable efficacy. Co-targeting of CDK9 and FLT3 is a promising two-pronged strategy to overcome resistance as the former plays a role in the transcription of Cancer cell-survival genes. Most prominently, Mcl-1 is known to be associated with AML tumorigenesis and drug resistance and can be down-regulated by CDK9 inhibition. We have developed CDDD11-8 as a potent CDK9 Inhibitor co-targeting FLT3-ITD with Ki values of 8 and 13 nM, respectively. The kinome selectivity has been confirmed when the compound was tested in a panel of 369 human kinases. CDDD11-8 displayed antiproliferative activity against leukemia cell lines, and particularly potent effects were observed against MV4-11 and MOLM-13 cells, which are known to harbor the FLT3-ITD mutation and mixed lineage leukemia (MLL) fusion proteins. The mode of action was consistent with inhibition of CDK9 and FLT3-ITD. Most importantly, CDDD11-8 caused a robust tumor growth inhibition by oral administration in animal xenografts. At 125 mg/kg, CDDD11-8 induced tumor regression, and this was translated to an improved survival of Animals. The study demonstrates the potential of CDDD11-8 towards the future development of a novel AML treatment.

Keywords

CDK9; FLT3; cancer; leukemia; targeted therapy.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-162037
    99.62%, CDK9/FLT3 Inhibitor